592 related articles for article (PubMed ID: 26116271)
1. Molecular Pathways: Activating T Cells after Cancer Cell Phagocytosis from Blockade of CD47 "Don't Eat Me" Signals.
McCracken MN; Cha AC; Weissman IL
Clin Cancer Res; 2015 Aug; 21(16):3597-601. PubMed ID: 26116271
[TBL] [Abstract][Full Text] [Related]
2. The interaction between signal regulatory protein alpha (SIRPα) and CD47: structure, function, and therapeutic target.
Barclay AN; Van den Berg TK
Annu Rev Immunol; 2014; 32():25-50. PubMed ID: 24215318
[TBL] [Abstract][Full Text] [Related]
3. The CD47-SIRPα signaling axis as an innate immune checkpoint in cancer.
Matlung HL; Szilagyi K; Barclay NA; van den Berg TK
Immunol Rev; 2017 Mar; 276(1):145-164. PubMed ID: 28258703
[TBL] [Abstract][Full Text] [Related]
4. Development of AO-176, a Next-Generation Humanized Anti-CD47 Antibody with Novel Anticancer Properties and Negligible Red Blood Cell Binding.
Puro RJ; Bouchlaka MN; Hiebsch RR; Capoccia BJ; Donio MJ; Manning PT; Frazier WA; Karr RW; Pereira DS
Mol Cancer Ther; 2020 Mar; 19(3):835-846. PubMed ID: 31879362
[TBL] [Abstract][Full Text] [Related]
5. Elimination of tumor by CD47/PD-L1 dual-targeting fusion protein that engages innate and adaptive immune responses.
Liu B; Guo H; Xu J; Qin T; Guo Q; Gu N; Zhang D; Qian W; Dai J; Hou S; Wang H; Guo Y
MAbs; 2018; 10(2):315-324. PubMed ID: 29182441
[TBL] [Abstract][Full Text] [Related]
6. CD47 Enhances In Vivo Functionality of Artificial Antigen-Presenting Cells.
Bruns H; Bessell C; Varela JC; Haupt C; Fang J; Pasemann S; Mackensen A; Oelke M; Schneck JP; Schütz C
Clin Cancer Res; 2015 May; 21(9):2075-83. PubMed ID: 25593301
[TBL] [Abstract][Full Text] [Related]
7. Soluble extracellular domains of human SIRPα and CD47 expressed in Escherichia coli enhances the phagocytosis of leukemia cells by macrophages in vitro.
Lin Y; Yan XQ; Yang F; Yang XW; Jiang X; Zhao XC; Zhu BK; Liu L; Qin HY; Liang YM; Han H
Protein Expr Purif; 2012 Sep; 85(1):109-16. PubMed ID: 22813925
[TBL] [Abstract][Full Text] [Related]
8. Nanocages displaying SIRP gamma clusters combined with prophagocytic stimulus of phagocytes potentiate anti-tumor immunity.
Choi Y; Nam GH; Kim GB; Kim S; Kim YK; Kim SA; Kim HJ; Lee EJ; Kim IS
Cancer Gene Ther; 2021 Sep; 28(9):960-970. PubMed ID: 34349240
[TBL] [Abstract][Full Text] [Related]
9. Cancer immunotherapy targeting the CD47/SIRPα axis.
Weiskopf K
Eur J Cancer; 2017 May; 76():100-109. PubMed ID: 28286286
[TBL] [Abstract][Full Text] [Related]
10. Exosome-SIRPα, a CD47 blockade increases cancer cell phagocytosis.
Koh E; Lee EJ; Nam GH; Hong Y; Cho E; Yang Y; Kim IS
Biomaterials; 2017 Mar; 121():121-129. PubMed ID: 28086180
[TBL] [Abstract][Full Text] [Related]
11. Absence of CD47 in vivo influences thymic dendritic cell subset proportions but not negative selection of thymocytes.
Guimont-Desrochers F; Beauchamp C; Chabot-Roy G; Dugas V; Hillhouse EE; Dusseault J; Langlois G; Gautier-Ethier P; Darwiche J; Sarfati M; Lesage S
Int Immunol; 2009 Feb; 21(2):167-77. PubMed ID: 19147837
[TBL] [Abstract][Full Text] [Related]
12. The role of CD47-SIRPα immune checkpoint in tumor immune evasion and innate immunotherapy.
Li Z; Li Y; Gao J; Fu Y; Hua P; Jing Y; Cai M; Wang H; Tong T
Life Sci; 2021 May; 273():119150. PubMed ID: 33662426
[TBL] [Abstract][Full Text] [Related]
13. TTI-621 (SIRPαFc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte Binding.
Petrova PS; Viller NN; Wong M; Pang X; Lin GH; Dodge K; Chai V; Chen H; Lee V; House V; Vigo NT; Jin D; Mutukura T; Charbonneau M; Truong T; Viau S; Johnson LD; Linderoth E; Sievers EL; Maleki Vareki S; Figueredo R; Pampillo M; Koropatnick J; Trudel S; Mbong N; Jin L; Wang JC; Uger RA
Clin Cancer Res; 2017 Feb; 23(4):1068-1079. PubMed ID: 27856600
[No Abstract] [Full Text] [Related]
14. Targeting CD47 in Anaplastic Thyroid Carcinoma Enhances Tumor Phagocytosis by Macrophages and Is a Promising Therapeutic Strategy.
Schürch CM; Roelli MA; Forster S; Wasmer MH; Brühl F; Maire RS; Di Pancrazio S; Ruepp MD; Giger R; Perren A; Schmitt AM; Krebs P; Charles RP; Dettmer MS
Thyroid; 2019 Jul; 29(7):979-992. PubMed ID: 30938231
[No Abstract] [Full Text] [Related]
15. Novel SIRPα Antibodies That Induce Single-Agent Phagocytosis of Tumor Cells while Preserving T Cells.
Andrejeva G; Capoccia BJ; Hiebsch RR; Donio MJ; Darwech IM; Puro RJ; Pereira DS
J Immunol; 2021 Feb; 206(4):712-721. PubMed ID: 33431660
[TBL] [Abstract][Full Text] [Related]
16. Development of Bispecific Antibody Derivatives for Cancer Immunotherapy.
He Y; Helfrich W; Bremer E
Methods Mol Biol; 2019; 1884():335-347. PubMed ID: 30465214
[TBL] [Abstract][Full Text] [Related]
17. SLAMF7 is critical for phagocytosis of haematopoietic tumour cells via Mac-1 integrin.
Chen J; Zhong MC; Guo H; Davidson D; Mishel S; Lu Y; Rhee I; Pérez-Quintero LA; Zhang S; Cruz-Munoz ME; Wu N; Vinh DC; Sinha M; Calderon V; Lowell CA; Danska JS; Veillette A
Nature; 2017 Apr; 544(7651):493-497. PubMed ID: 28424516
[TBL] [Abstract][Full Text] [Related]
18. SIRPα-CD47 Immune Checkpoint Blockade in Anticancer Therapy.
Veillette A; Chen J
Trends Immunol; 2018 Mar; 39(3):173-184. PubMed ID: 29336991
[TBL] [Abstract][Full Text] [Related]
19. Loss of Cell Surface CD47 Clustering Formation and Binding Avidity to SIRPα Facilitate Apoptotic Cell Clearance by Macrophages.
Lv Z; Bian Z; Shi L; Niu S; Ha B; Tremblay A; Li L; Zhang X; Paluszynski J; Liu M; Zen K; Liu Y
J Immunol; 2015 Jul; 195(2):661-71. PubMed ID: 26085683
[TBL] [Abstract][Full Text] [Related]
20. Engineering macrophages to eat cancer: from "marker of self" CD47 and phagocytosis to differentiation.
Alvey C; Discher DE
J Leukoc Biol; 2017 Jul; 102(1):31-40. PubMed ID: 28522599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
